Page last updated: 2024-12-08

ferrous gluconate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth

Description

ferrous gluconate: iron important in this cpd; RN given refers to ferrous cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16212939
MeSH IDM0058413

Synonyms (5)

Synonym
ferrous gluconate
299-29-6
iron(ii) gluconate
ferrous gluconate hydrate
iron (ii) gluconate hydrate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In the parental generation, too, adverse effects of Mg-L were aggravated by Mg-L/Fe-L despite the fact that no iron accumulation occurred."( Potentiation of magnesium-deficiency-induced foetotoxicity by concomitant iron deficiency and its prevention by adequate supply via drinking water.
Bubeck, J; Classen, HG; Disch, G; Haussecker, H; Spätling, L, 1994
)
0.29
" During the maintenance phase (period of epoetin therapy after correction of iron deficiency), the use of low-dose intravenous iron supplementation (10 to 20 mg per haemodialysis treatment or 100 mg every second week) avoids iron overtreatment and minimises potential adverse effects."( Safety aspects of parenteral iron in patients with end-stage renal disease.
Hörl, WH; Sunder-Plassmann, G, 1997
)
0.3
" There were no adverse effects observed on acute toxicity test."( [Effect of hemin in treating hemorrhagic anemia and toxicity].
Huang, MH; Huang, ZQ; Pan, LJ; Wu, B; Wu, GT; You, KS; Zhang, C; Zhao, ZQ, 1996
)
0.29
"Hemin had a better effect than FG and no adverse effect was found in hemin."( [Effect of hemin in treating hemorrhagic anemia and toxicity].
Huang, MH; Huang, ZQ; Pan, LJ; Wu, B; Wu, GT; You, KS; Zhang, C; Zhao, ZQ, 1996
)
0.29
" The LD50 values of 1775 and 1831 mg SFG/kg body wt were obtained for female and male rats, respectively, evidencing that SFG can be considered as a safe compound from a toxicological point of view."( Stabilized ferrous gluconate as iron source for food fortification: bioavailability and toxicity studies in rats.
Boccio, JR; Caro, RA; Ettlin, E; Leonardi, NM; Lysionek, AE; Salgueiro, MJ; Zubillaga, MB, 2003
)
0.32

Bioavailability

The effect of ferrous sulphate (300 mg), ferrous gluconate (600 mg), and a combination tablet of iron (10 mg), magnesium (100 mg), zinc (15 mg) (Centrum Forte) co-administration on ciprofloxacin bioavailability was tested in eight healthy subjects.

ExcerptReferenceRelevance
" The effect of ferrous sulphate (300 mg), ferrous gluconate (600 mg), and a combination tablet of iron (10 mg), magnesium (100 mg), zinc (15 mg), calcium (162 mg), copper (2 mg), and manganese (5 mg) (Centrum Forte) co-administration on ciprofloxacin bioavailability was tested in eight healthy subjects."( Clinical and chemical interactions between iron preparations and ciprofloxacin.
Campbell, NR; Hasinoff, BB; Kara, M; McKay, DW, 1991
)
0.28
" Bioavailability of iron was not impaired by magnesium as MAH."( Potentiation of magnesium-deficiency-induced foetotoxicity by concomitant iron deficiency and its prevention by adequate supply via drinking water.
Bubeck, J; Classen, HG; Disch, G; Haussecker, H; Spätling, L, 1994
)
0.29
"The iron bioavailability and acute oral toxicity in rats of a ferrous gluconate compound stabilized with glycine (SFG), designed for food fortification, was studied in this work by means of the prophylactic method and the Wilcoxon method, respectively."( Stabilized ferrous gluconate as iron source for food fortification: bioavailability and toxicity studies in rats.
Boccio, JR; Caro, RA; Ettlin, E; Leonardi, NM; Lysionek, AE; Salgueiro, MJ; Zubillaga, MB, 2003
)
0.32
"In this research, we measured the iron bioavailability of ferrous gluconate stabilized with glycine (SFG) when it is used to fortify petit suisse cheese using the prophylactic-preventive method in rats."( Iron bioavailability from fortified petit suisse cheese determined by the prophylactic-preventive method.
Barrado, A; Boccio, J; Janjetic, M; Orlandini, J; Torti, H; Urriza, R; Weill, R, 2006
)
0.33
"High doses of oral iron were well absorbed and tolerated in PD patients."( [Resorption and tolerance of the high doses of ferrous sulfate and ferrous gluconate in the patients on peritoneal dialysis].
Grujić-Adanja, G; Ignjatović, S; Jovanović, N; Lausević, M; Stojimirović, B, 2006
)
0.33
" This study aims to investigate the bioavailability of ferrous gluconate stabilised with glycine (FGSG) in a fresh cheese fortified with zinc."( Bioavailability of stabilised ferrous gluconate with glycine in fresh cheese matrix: a novel iron compound for food fortification.
Boccio, J; Carmuega, E; Frereux, M; Marque, S; Noirt, F; Olivares, M; Pizarro, F; Salgueiro, M; Weill, R, 2013
)
0.39
" The iron bioavailability of non-heme iron, in the presence of egg white (EW) hydrolysates, was evaluated in vitro using a tissues culture model system - rat intestinal epithelial cells (IEC-6)."( Effects of different proteases on iron absorption property of egg white hydrolysates.
Horimoto, Y; Lim, LT, 2017
)
0.46
" Elevating dietary micronutrient iron (Fe) intake can reduce Pb oral bioavailability while being beneficial for child nutritional health."( Effects of various Fe compounds on the bioavailability of Pb contained in orally ingested soils in mice: Mechanistic insights and health implications.
Juhasz, AL; Li, HB; Li, SW; Lin, XY; Ma, LQ; Wang, HY; Xue, RY; Zhang, S; Zhang, YS; Zhou, DM; Zhou, L, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Taking both electrolytes together instead of 2 to 3 h apart from each other, as actually recommended, means a less complicated dosage regimen and probably improves compliance."( Therapeutic availability of iron administered orally as the ferrous gluconate together with magnesium-L-aspartate hydrochloride.
Classen, HG; Disch, G; Leifert, U; Schumacher, E; Spätling, L, 1996
)
0.29
" Adequate intravenous iron supplementation allows reduction of epoetin dosage by approximately 40%."( Safety aspects of parenteral iron in patients with end-stage renal disease.
Hörl, WH; Sunder-Plassmann, G, 1997
)
0.3
"Fifty rats with hemorrhagic anemia were randomly divided into 5 groups with different dosage of hemin (93, 168, 300 mg."( [Effect of hemin in treating hemorrhagic anemia and toxicity].
Huang, MH; Huang, ZQ; Pan, LJ; Wu, B; Wu, GT; You, KS; Zhang, C; Zhao, ZQ, 1996
)
0.29
" This study further shows that Chemiron has a better haematological effect than Ferrous Gluconate at the dosage used."( The effect of 61 days of combined iron (Chemiron) and single iron therapy on haemoglobin, packed cell volume, platelets and reticulocytes during pregnancy. Preliminary report.
Ajayi, GO; Fadiran, EO, 1998
)
0.3
" This reaction may be used as an important consideration to optimize the dosing regime of the two drugs and to help explain some pharmacological reactions between aspirin and biomolecules."( A Reaction of Aspirin with Ferrous Gluconate.
Zhang, J, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Pet Supplies1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Natural Dog Company Multivitamin Supplements For Dogs -- 90 Soft ChewsNatural Dog CompanyPet Suppliesascorbic acid, beta carotene, vitamin B7, Choline, Vitamin E, ferrous gluconate, Folic Acid, vitamin E, inositol, Iodine, Manganese, Niacin, Pantothenic Acid, potassium iodate, pyridoxine hydrochloride, vitamin B6, vitamin A acetate, Vitamin A, vitamin B2, Selenium, vitamin B1, Vitamin B12, vitamin B6, vitamin K2024-11-29 10:47:42

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (16.47)18.7374
1990's18 (21.18)18.2507
2000's27 (31.76)29.6817
2010's22 (25.88)24.3611
2020's4 (4.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (33.70%)5.53%
Reviews5 (5.43%)6.00%
Case Studies4 (4.35%)4.05%
Observational1 (1.09%)0.25%
Other51 (55.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors [NCT02245321]702 participants (Actual)Interventional2011-06-30Completed
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot [NCT02233322]8 participants (Actual)Interventional2014-08-31Completed
[NCT02228902]Phase 424 participants (Actual)Interventional2014-08-31Completed
Health Economics of the Use of Ferrous Iron Salts in Primary Care in the UK. [NCT02300428]406,902 participants (Actual)Observational2014-11-30Completed
South African Paediatric Surgical Outcomes Study-2 (SAPSOS-2). A South African Multi-centre Pilot Trial to Assess the Feasibility and Clinical Efficacy of Preoperative Oral Iron to Treat Preoperative Iron-deficiency Anaemia in Children Undergoing Elective [NCT05681871]Phase 2/Phase 3420 participants (Anticipated)Interventional2023-01-16Not yet recruiting
Iron Prehabilitation and Perioperative Infectious Diseases of Endometrial Cancer Patients [NCT06049693]Phase 4100 participants (Anticipated)Interventional2023-01-01Enrolling by invitation
[NCT00248716]Phase 4200 participants (Anticipated)Interventional2007-02-28Recruiting
Study to Measure the Absorption of Iron From Ferrous Gluconate Incorporated Into Alginate Beads. [NCT01528644]16 participants (Actual)Interventional2012-02-29Completed
Hemoglobin and Iron Recovery Study [NCT01555060]Phase 2215 participants (Actual)Interventional2012-03-31Completed
[NCT02271997]Phase 4120 participants (Actual)Interventional2014-12-04Completed
Iron Depletion and Replacement in Blood Donors [NCT01752413]197 participants (Actual)Interventional2012-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01752413 (2) [back to overview]Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation
NCT01752413 (2) [back to overview]Number of Participants With Improved Ferritin Levels on Subsequent Visit

Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation

Subject self reported habits for taking iron supplement or iron rich diet and severity of gastrointestinal complaints (minimal-1 to severe-5). GI complaints were not separated by type for analysis. (NCT01752413)
Timeframe: Two years

InterventionParticipants (Count of Participants)
Ferrous Gluconate 325mg116
Nutrition Counseling17

[back to top]

Number of Participants With Improved Ferritin Levels on Subsequent Visit

Compared ferritin levels at baseline and after iron replacement therapy among blood donors, adjusting for time between visits, participant adherence levels, and whether a unit was donated at second visit. (NCT01752413)
Timeframe: Two years

InterventionParticipants (Count of Participants)
Ferrous Gluconate 325mg73
Nutrition Counseling6

[back to top]